ESMO Sarcoma and Rare Cancers 2023 | Chemotherapy as a pre-treatment to subvert ICI resistance in STS

Zuzana Strizova, MD, PhD, Charles University, Prague, Czech Republic, discusses the promising therapeutic potential of employing combinatorial treatment approaches for soft tissue sarcomas (STS) to combat drug resistance arising from immune checkpoint inhibitors (ICI). Dr Strizova details that incorporating chemotherapy may improve outcomes as chemotherapy has been shown to increase CD8+ T-cells in the tumor microenvironment and may also selectively exhaust suppressive regulatory T-cells. This interview took place at the ESMO Sarcoma and Rare Cancers Congress 2023 in Lugano, Switzerland.

These works are owned by Magdalen Medical Publishing (MMP) and are protected
by copyright laws and treaties around the world. All rights are reserved.